Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from D. Boral Capital

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $2.00 target price on the stock. D. Boral Capital’s target price indicates a potential upside of 238.93% from the stock’s previous close.

Separately, HC Wainwright raised their price target on shares of Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th.

Lineage Cell Therapeutics Trading Up 14.6 %

Shares of NYSEAMERICAN LCTX opened at $0.59 on Friday. The firm has a market capitalization of $130.07 million, a price-to-earnings ratio of -4.92 and a beta of 1.16. Lineage Cell Therapeutics has a one year low of $0.48 and a one year high of $1.61.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its position in shares of Lineage Cell Therapeutics by 13.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 677,162 shares of the company’s stock worth $613,000 after buying an additional 82,864 shares during the last quarter. Barclays PLC lifted its holdings in shares of Lineage Cell Therapeutics by 311.3% in the third quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after acquiring an additional 159,924 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Lineage Cell Therapeutics by 2.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock valued at $3,331,000 after purchasing an additional 83,274 shares in the last quarter. State Street Corp boosted its stake in shares of Lineage Cell Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,608,352 shares of the company’s stock valued at $2,361,000 after purchasing an additional 45,483 shares in the last quarter. Finally, Raffles Associates LP grew its holdings in shares of Lineage Cell Therapeutics by 3.4% during the 3rd quarter. Raffles Associates LP now owns 4,507,781 shares of the company’s stock valued at $4,081,000 after purchasing an additional 150,000 shares during the last quarter. 62.47% of the stock is owned by institutional investors.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.